Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-025 in mild eosinophilic HDM-allergic asthma
NL-OMON55388Phase 2Active, not recruiting
- Sponsor
- Foresee Pharmaceuticals
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of aderamastat in asthma (2 arms), sponsored by Foresee Pharmaceuticals. Primary endpoint: FEV1 AUC3-8h. Started May 2018; status: active, not recruiting.
02
Drugs
aderamastat
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON55388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55388.